# A drop in serum estradiol levels during GnRH antagonist cotreatment in cycles stimulated with gonadotropins is associated with lower cumulative live birth rates

**Authors:** Lara Janssens, Ella Roelant, Christophe Blockeel, Diane De Neubourg

PMC · DOI: 10.3389/fendo.2026.1722379 · Frontiers in Endocrinology · 2026-03-18

## TL;DR

A drop in estradiol after using GnRH antagonists during IVF is linked to lower chances of live births.

## Contribution

This study identifies a correlation between estradiol drops and reduced live birth rates in GnRH antagonist cycles.

## Key findings

- Estradiol drop is associated with lower ongoing pregnancy and live birth rates.
- Cycles with estradiol drops show a larger decrease in serum LH after GnRH antagonist use.
- Lower LH levels on ovulation day are observed in cycles with estradiol drops.

## Abstract

Over the last decades, the gonadotropin-releasing hormone (GnRH) antagonist protocol has become widely used for prevention of premature luteinizing hormone surge during ovarian stimulation with exogenous gonadotropins. Literature has shown its efficacy and safety, while maintaining similar live birth rates compared to agonist protocols. Clinicians occasionally notice a drop in serum estradiol levels after GnRH antagonist initiation. This study aimed to analyze the impact of a drop in serum estradiol levels after the administration of a GnRH antagonist on clinical outcomes in in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles. The results showed that estradiol drop was related to lower ongoing pregnancy, live birth and cumulative live birth rates. Estradiol drop was less frequent in cycles using gonadotropins containing luteinizing hormone (LH) activity and cycles with a drop showed a larger decrease in serum LH after the first GnRH antagonist administration, resulting in lower serum values on the day of ovulation triggering. These findings suggest that future prospective research could focus on potential optimization of luteinizing hormone (LH) levels and this study might also add to the discussion that estradiol monitoring could be useful in detecting cycles with an increased risk of less favorable outcomes.

## Full-text entities

- **Chemicals:** luteinizing hormone (MESH:D007986), GnRH antagonist (-), Estradiol (MESH:D004958)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13038525/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13038525/full.md

## References

33 references — full list in the complete paper: https://tomesphere.com/paper/PMC13038525/full.md

---
Source: https://tomesphere.com/paper/PMC13038525